Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Press Releases

[Paris, France & Geneva, Switzerland – 5 December 2013]
Research & Development for Diseases of the Poor: A 10-Year Analysis of Impact of the DNDi Model
Report provides real and estimated costs of repurposing drugs and new chemical entities, evoking the lessons learned based on alternative pathways and partnerships
Today, at a scientific meeting at Institut Pasteur, France, entitled ‘Best Science for the Most Neglected: Where Do We Stand Ten Years On?’, co-organized with Institut Pasteur and MSF and in collaboration with PLOS, the Drugs for Neglected Diseases initiative (DNDi) marks its 10-year anniversary by issuing a report that explores the lessons learned from a decade of research and development (R&D) of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. The report also comes at the time of discussions at the WHO aiming at gaining Member State agreement on ‘demonstration projects’ meant to provide evidence for the feasibility and sustainability of collaborative and open approaches to R&D for the health needs of developing countries.
[Deutsch] [Español] [Français] [Português]

More

[Cambridge, UK – 27 November, 2013]
New Collection from PLOS and DNDi highlights a decade of R&D into neglected tropical diseases
As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to be launching a special Collection—PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D (Research and Development)—to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10-year anniversary of DNDi.

More

[Washington, DC – 14 November, 2013]
Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
First placebo-controlled study in adults with Chagas disease highlights urgent need to scale up treatment for millions of patients at risk
According to results of the first-ever Phase 2 clinical trial in Bolivia, conducted by the Drugs for Neglected Diseases initiative (DNDi), the experimental drug candidate E1224 showed good safety and was effective at clearing the parasite that causes Chagas disease, but had little to no sustained efficacy one year after treatment as a single medication. On the other hand, standard therapy for Chagas, benznidazole, was shown to be effective in the long term but continued to be associated with side effects. The results, presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), highlight the need to investigate alternative dosing regimens and possible combination therapies to improve patient care.
[Español] [Português]

More

[Geneva, Switzerland – 11 November 2013]
Mundo Sano and DNDi Join Forces to Provide Access to Treatments for Chagas Disease Patients
Strategic agreement signed today to ensure crucial second source of pediatric formulation of benznidazole for millions of children in need of treatment
Today the Mundo Sano Foundation and the Drugs for Neglected Diseases initiative (DNDi) signed a wide-ranging accord to collaborate closely on a vital second source of the drug benznidazole for children affected by Chagas disease. From production to patient access, securing affordability and accessibility, the agreement unites the two not-for-profit organizations, highly involved in advocacy and drug research and development, in their common effort to fill treatment gaps for Chagas disease patients worldwide.
[Español] [Português]

More

[Geneva, Switzerland – 24 October 2013]
Deadly Gaps Persist in New Drug Development for Neglected Diseases
New study shows that, despite some progress, only 4% of new drugs and vaccines approved 2000-2011 were for neglected diseases, and a ‘fatal imbalance’ remains in R&D for many neglected patients
In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative (DNDi) and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development (R&D) efforts. This continued ‘fatal imbalance’ in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.
[Deutsch] [Español] [Français] [Português]

More

[Geneva, Switzerland – 22 August 2013]
UK Department for International Development (DFID) Commits £ 30 Million to DNDi
5-Year Grant Awarded to DNDi to Advance Research and Development for Neglected Diseases
The UK Department for International Development (DFID) has announced its renewed support to the Drugs for Neglected Diseases initiative (DNDi), allocating a total of £ 30 million (€ 35 million) over the coming five years (2013-2018) to DNDi’s Research & Development (R&D) portfolio to fight neglected diseases. This grant is part of DFID’s larger investment of £ 138 million in nine product development partnerships (PPDs), including DNDi, for the development of new health tools to address poverty-related diseases.

More

[Geneva, Switzerland – 30 July 2013]
The Swiss Agency for Development and Cooperation Reiterates Its Commitment to the Fight against Neglected Diseases
The Swiss Agency for Development and Cooperation (SDC) recently renewed its support for the Drugs for Neglected Diseases initiative (DNDi), allocating a total of CHF 8 million over the coming four years (2013-2016). The research and development for new treatments for neglected diseases contributes to the World Health Organization's global strategy to eliminate specific neglected tropical diseases by 2020.
[Deutsch] [Français]

More

[Geneva, Switzerland – 11 July 2013]
Three Neglected-Disease Treatments Newly Added to the WHO Essential Medicines List for Paediatric Use
Resulting from DNDi’s paediatric R&D, the treatments will improve the management of deadly malaria, African sleeping sickness, and Chagas disease in children
This week the World Health Organization (WHO) released its newly updated 4th WHO Model List of Essential Medicines for Children (EMLc), in which three treatments developed by the Drugs for Neglected Diseases initiative (DNDi) and its partners have now been included. One treatment was also added to the 18th WHO Model List of Essential Medicines (EML) for adults.

More

[Kuala Lumpur, Malaysia - 30 June 2013]
DNDi & Cipla Advance Development of Paediatric 4-in-1 ARVs to Fulfill New WHO Guidelines
Immediate, Expanded, and Improved Treatments Needed for Infants and Toddlers with HIV
The World Health Organization’s new HIV treatment guidelines, released today at the 2013 International AIDS Society (IAS) Conference, include new antiretroviral (ARV) therapy (ART) recommendations for HIV-infected children, and will mean that more children will be on better treatments. The Drugs for Neglected Diseases initiative (DNDi) applauds the new guidelines and, with Cipla Ltd. and other partners, is expediting the development of urgently needed 4-in-1 ARVs adapted for babies and toddlers with HIV, to be delivered by 2015.

More

[Madrid, Spain - June 18, 2013]
DNDi Receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation - DNDi is testing new treatments against sleeping sickness, leishmaniasis, Chagas disease, and pediatric HIV
For those familiar with the field of neglected diseases, it goes by the name of the 10/90 gap: only 10 per cent of global health research was devoted to conditions that accounted for 90 per cent of the global disease burden. It was to counteract this imbalance that the Drugs for Neglected Diseases initiative (DNDi) came into being in 2003. Coinciding with its tenth anniversary year, the organization has been granted the BBVA Foundation Frontiers of Knowledge Award in the Development Cooperation category. Its Executive Director, Bernard Pécoul, announced this morning at a press conference that new drugs DNDi is working on “could dramatically change the management of some of these neglected diseases.”
[Español]

More

[Nairobi, Kenya - 5 June 2013]
Ten Years of Health Innovation in Africa: Progress Made But Sustained Engagement and Partnership Needed to Develop and Implement New, Adapted Treatments for Neglected Diseases
Days after two landmark resolutions were adopted at the World Health Assembly – on neglected tropical diseases and on research and development (R&D), financing and coordination for the health needs of developing countries – over 400 scientists, representatives and ministers of health, ambassadors, national control programme representatives, African regulators, health workers, public health experts, and activists from 21 African countries and 10 others from around the world gather in Nairobi to take stock of health innovation for neglected diseases in Africa over the past decade. While progress has been made, and certain diseases are targeted for elimination, the need for strong leadership, coordination, and sustainable funding is as pressing as ever and is critical to achieving much-needed breakthroughs.

More

[New York, NY, USA and Geneva, Switzerland – 2 May 2013]
DNDi Selected as Finalist for Rockefeller Foundation’s “Next Century Innovators Award”
Public Voting Underway Through May 31 – Finalist with Most Votes Will Receive Award
The Drugs for Neglected Diseases initiative (DNDi) was selected as one of two finalists for the Rockefeller Foundation’s “Next Century Innovators Awards”, recognizing innovative organizations working to improve conditions for vulnerable populations around the world.

More

[Paris, France, and Geneva, Switzerland– 25 April 2013]
Sanofi and DNDi celebrate six years of collaboration in fighting malaria by distributing 200 million treatments of ASAQ
On World Malaria Day
Sanofi (EURONEXT, SAN and NYSE;SNY) and the Drugs for Neglected Diseases initiative (DNDi), an independent not-for-profit foundation, announce that on the occasion of World Malaria Day, more than 200 million treatments of ASAQ Winthrop have been distributed in Africa since the medication became available in 2007.
[PDF] [Français]

More

[Geneva, Switzerland and Nairobi, Kenya – 23 April 2013]
International Consortium, To Bring New Treatments for Kala-Azar Patients in East Africa, Receives Funding Boost from European Union
Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of €3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.

More

[Geneva, Switzerland – 22 April 2013]
Swiss Malaria Group announces winners of malaria photo contest
On the occasion of World Malaria Day 2013, the Swiss Malaria Group announce the winners of the photo contest “Malaria: The Big Picture”. The online photo contest and subsequent exhibition was organised by the Swiss Malaria Group to highlight the reality of those living at risk of malaria and the work of those dedicated to changing that reality.
[Click here to view the winning photos from each category][Français] [Deutsch]

More

[Cochabamba, Bolivia – 16 April 2013]
Specialists from around the world have gathered in Cochabamba, Bolivia to discuss projects to improve the health and quality of life of those affected by Chagas disease
“Chagas Week: Neglected Disease” gathers doctors, specialists, researchers and authorities to discuss issues related to the disease that affects up to 8 million people worldwide, mostly in Latin America, according to the World Health Organization.
[PDF][Español] [Português]

More

[Mexico City – 10 April 2013]
DNDi Latin America Pledges 2013 Carlos Slim Health Award to Chagas Disease
This silent killer urgently needs a coordinated response and action plan
The Drugs for Neglected Diseases initiative (DNDi) Latin America today announced that it will pledge the US $100,000 Carlos Slim Health Award to Chagas disease, the leading parasitic killer of the Americas..

More

[Tokyo, Japan, and Geneva, Switzerland – 8 April 2013]
DNDi Welcomes the Global Health Innovative Technology Fund (GHIT Fund)
New Japan-Driven Initiative to Accelerate Research & Development Innovation for Neglected Diseases
The Drugs for Neglected Diseases initiative (DNDi), based in Geneva, Switzerland, and DNDi Japan, based in Tokyo, welcome the launch of the Global Health Innovative Technology Fund (GHIT Fund), an initiative supported by the Japanese government, several Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation. [Japanese - in pdf]

More

[Geneva, Switzerland - 27 February 2013]
DNDi Welcomes Medicines Patent Pool Collaboration Agreement with ViiV Healthcare as Important Precedent for Facilitating Development of Paediatric ARV Formulations
The Drugs for Neglected Diseases initiative (DNDi) welcomes today’s announcement by the Medicines Patent Pool of a new collaboration with ViiV Healthcare. This collaboration will facilitate the development of urgently needed, new paediatric ARV formulations through the licensing of patents from various companies.

More

[Geneva, Switzerland - 26 February 2013]
DNDi Receives BBVA Foundation Award for Development Cooperation for Delivering New Treatments for Neglected Diseases
Today in Madrid, Spain, the Drugs for Neglected Diseases initiative (DNDi) received the BBVA Foundation ‘Frontiers of Knowledge and Culture Award for Development Cooperation’. This EUR 400,000 award will be presented at a ceremony in Madrid, Spain, in June of this year.

More

[Rio de Janeiro, Brazil, Geneva, Switzerland, 15 February 2013]
DNDi Latin America receives 2013 Carlos Slim Award for Innovations in Neglected Disease Drug Development
Today the Drugs for Neglected Diseases initiative (DNDi) in Latin America received the Carlos Slim Health Award for 10 years of exceptional work and achievements in research and development (R&D) to deliver new treatments for neglected patients in the region. The $100,000 award will be presented at a ceremony in April in Mexico City.
[PDF] [Español] [Português]

More



Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License